Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Primary objective: To demonstrate the non-inferiority of acetylsalicylic acid (ASA) to
anticoagulant treatment (vitamin K antagonists) in CAD-patients with regard to outcome and
complication measures.
Methods: Randomized controlled, open labeled multicenter, non-inferiority trial with blinded
assessment of outcome events.
Primary endpoint: Primary composite outcome measure - labeled Cerebrovascular Ischemia, major
Hemorrhagic events or Death (CIHD) - includes the following efficacy and safety outcome
measures during the treatment period: (i) occurrence of any stroke*, new acute lesions on
diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial
hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.
Phase:
Phase 4
Details
Lead Sponsor:
Stefan Engelter University Hospital, Basel, Switzerland
Collaborators:
University Hospital Inselspital, Berne University of Lausanne Hospitals
Treatments:
Acenocoumarol Aspirin Phenprocoumon Vitamin K Vitamins Warfarin